很抱歉,您的瀏覽器過於老舊無法閱讀網頁內容的需要,請更新瀏覽器或安裝 Google Chrome.
Bringing Hope to Life
Bringing Hope to Life
Senhwa is a precision therapy company focusing on developing First-in-Class therapeutics for patients with unmet medical needs. These include multiple programs for gene-mutated cancers, rare diseases, and novel coronaviruses.
OUR PIPELINE
Coronavirus Curative
Coronavirus Curative
The first patient treated with Senhwa’s Silmitasertib (CX-4945) for severe COVID-19 demonstrated remarkable recovery and was discharged in 5 days after treatment.
OUR CLINICAL TRIALS
One Drug with Multi-target Therapy
One Drug with Multi-target Therapy
Senhwa’s Pidnarulex (CX-5461) has proven to be the next generation DDR (DNA Damage Response) drug, with the mechanism of synthetic lethality across multiple tumor types in patients with loss of function of tumor suppressor genes such as HRD (Homologous Recombination Deficiency) and beyond, and has great potential for patients who have developed resistance to PARP inhibitors and platinum or other chemotherapies.
OUR PLATFORM
Pioneering the Paradigm
Pioneering the Paradigm
Senhwa strives to design and develop innovative therapies rooted in our leading expertise in protein kinases inhibition, and improve quality of life for cancer patients. .
OUR COMPANY

Latest News

December 25, 2023
Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection
November 21, 2023
Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection

Media and Events

November 09, 2023
Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19
October 19, 2023
Senhwa Biosciences Announces IND Submission to US FDA for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection

Senhwa Biosciences' drug product, Silmitasertib (CX-4945), blocks CK2- potentially stopping SARS-Cov-2 in its tracks

Clinical Programs

Publications

Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

OUR VISION

“As a value added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof of Concept”
- Dr. Jin-Ding Huang , CEO